RedHill Biopharma
Redhill Biopharma Ltd is an Israel-basedis a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The Company promotes three gastrointestinal drugs in the US: Movantik, Talicia and Aemcolo. Key programs in it pipeline of late-stage clinical assets include: opaganib (Yeliva) and RHB-107 for multiple indications including COVID-19, RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease and RHB-104 for Crohn's disease.